Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The MedSurg and Neurotechnology segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. This segment also provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke; and craniomaxillofacial implant products, including cranial, maxillofacial, and chest wall devices, as well as dural substitutes and sealants. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
Employees - 52000,
CEO - Mr. Kevin A. Lobo,
Sector - Healthcare,
Country - US,
Market Cap - 141.89B
Altman ZScore(max is 10): 5.13, Piotroski Score(max is 10): 6, Working Capital: $7004000000, Total Assets: $43833000000, Retained Earnings: $18303000000, EBIT: 4445000000, Total Liabilities: $23684000000, Revenue: $21974000000
AryaFin Target Price - $202.86 - Current Price $364.60 - Analyst Target Price $414.68
| Ticker | SYK |
| Index | S&P 500 |
| Curent Price | 364.60 |
| Change | 2.09% |
| Market Cap | 141.89B |
| Average Volume | 1.21M |
| Income | 3.59B |
| Sales | 21.97B |
| Book Value/Share | 52.86 |
| Cash/Share | 12.04 |
| Dividend Est | 3.15 (0.86%) |
| Dividend TTM | 3.20 (0.88%) |
| Dividend Ex-Date | Dec 31, 2024 |
| Employees | 52000 |
| Moving Avg 20days | -3.95% |
| Moving Avg 50days | -2.52% |
| Moving Avg 200days | 3.76% |
| Shares Outstanding | 381.20M |
| Earnings Date | Oct 29 AMC |
| Inst. Ownership | 80.55% |
| Price/Earnings | 39.09 |
| Forwad P/E | 26.99 |
| PE Growth | 3.80 |
| Price/Sales | 6.46 |
| Price/Book | 6.90 |
| Price/Cash | 30.29 |
| Price/FCF | 44.27 |
| Quick Ratio | 1.22 |
| Current Ratio | 1.91 |
| Debt/Equity | 0.79 |
| Return on Assets | 8.77% |
| Return on Equity | 18.87% |
| Return on Investment | 10.61% |
| Gross Margin | 61.28% |
| Ops Margin | 21.58% |
| Profit Margin | 16.34% |
| RSI | 38.87 |
| BETA(β) | 0.95 |
| From 52week Low | 26.53% |
| From 52week High | -8.44% |
| EPS | 9.33 |
| EPS next Year | 13.51 |
| EPS next Qtr | 3.87 |
| EPS this Year | 13.73% |
| EPS next 5 Year | 10.30% |
| EPS past 5 Year | -2.45% |
| Sales past 5 Year | 8.80% |
| EPS Y/Y | 38.41% |
| Sales Y/Y | 10.51% |
| EPS Q/Q | 20.02% |
| Sales Q/Q | 11.92% |
| Sales Surprise | 2.26% |
| EPS Surprise | 3.52% |
| ATR(14) | 7.09 |
| Perf Week | -2.67% |
| Perf Month | -5.47% |
| Perf Quarter | -0.53% |
| Perf Year | 26.46% |
| Perf YTD | 21.75% |
| Target Price | 414.68 |
AryaFin Engine© - An AI FinTech Venture - 2024 Disclaimer